“…Allogeneic haematopoietic stem cell transplantation (allo‐HSCT) is a potentially curative treatment for patients with haematological malignancies (Giralt et al., ; Majhail et al., ), which is increasingly being used worldwide (Nivison‐Smith et al., ; Passweg et al., ; Yoshimi et al., ). The standard procedure for myeloablative allo‐HSCT includes a conditioning regimen of high‐dose chemotherapy, often in combination with total‐body irradiation (TBI), followed by infusion of stem cells harvested from a donor's bone marrow or peripheral blood (Imamura & Shigematsu, ; Mikell et al., ). This conditioning regimen produces a 2–4 week period of cytopenia, characterised by severe leukopenia and thrombocytopenia, requiring the patient to be in a single‐bed isolation room for 4–6 weeks (Morishita, Kaida, Setogawa, et al., ).…”